Developing a pharmaceutical product containing a high risk for potential abuse Schedule II controlled substance requires more than formulation and manufacturing expertise. Sponsors must account for additional requirements involving material control, security, documentation, inventory reconciliation, facility controls, and regulatory compliance.
For pharmaceutical and biotechnology companies developing controlled substance products, selecting a CDMO with the appropriate Drug Enforcement Administration (DEA) authorization can affect how efficiently a program moves from early formulation development into scale-up and manufacturing.
Ascendia Pharmaceutical Solutions holds a DEA Schedule II registration and combines controlled substance handling capabilities with formulation development, analytical services, and cGMP manufacturing. This integrated approach allows sponsors to address the scientific and operational requirements of controlled substance development through a single U.S.-based CDMO.
What Does a DEA Schedule II Registration Enable?
DEA Schedule II substances are subject to strict controls because they have recognized medical applications while also carrying potential risks associated with abuse, dependence, or diversion.
For a pharmaceutical CDMO, the ability to work with these substances requires more than obtaining a registration. Appropriate facility infrastructure, security measures, standard operating procedures, documentation, personnel, and inventory controls must support the handling of incoming controlled materials.
Ascendia Pharmaceutical Solutions obtained its DEA Schedule II registration to expand its ability to support pharmaceutical companies developing controlled substance products. The registration complements existing capabilities for Schedule III–V controlled substances and allows Ascendia Pharmaceutical Solutions to support a broader range of controlled substance development and manufacturing programs.
Why Controlled Substance CDMO Capabilities Matter
Controlled substances have important therapeutic applications, including medications used to manage severe pain and acute medical conditions. The regulatory controls surrounding these products do not eliminate their therapeutic value or the need for pharmaceutical development and manufacturing capabilities.
For sponsors, the challenge is finding a CDMO that can address both sides of the program.
The development partner must understand the formulation and manufacturing requirements of the drug product while also maintaining the controls required for the substance itself.
A CDMO without the appropriate DEA authorization cannot simply accept a Schedule II controlled substance and perform development or manufacturing activities with it. Sponsors may need to identify additional partners, transfer materials between facilities, or separate formulation, analytical, and manufacturing activities among multiple organizations.
Those additional handoffs can create more challenges associated with delays, additional project management requirements, and increased costs.
Controlled Substance Handling Requires Additional Controls
Schedule II programs require a higher level of operational control than conventional pharmaceutical development programs.
Controlled materials must be appropriately received, stored, accessed, used, documented, and reconciled. Security systems and restricted-access areas help protect controlled materials, while standard operating procedures (SOPs) define how personnel manage those materials throughout development and manufacturing.
Ascendia Pharmaceutical Solutions maintains controlled-access storage, security systems, surveillance, documented procedures, and inventory reconciliation log book processes to support its DEA requirements.
The facility has also undergone the DEA inspection associated with its Schedule II registration.
Controlled and non-controlled materials also require appropriate separation and facility controls. Ascendia Pharmaceutical Solutions uses isolators and other controls to reduce the potential for cross-contamination between controlled-substance projects and other pharmaceutical programs.
These requirements add personnel, documentation, oversight, and operational responsibilities to a development program. A CDMO must have the systems and resources to manage those requirements without disrupting the scientific work needed to advance the drug product.
What Ascendia Pharmaceutical Solutions Can Provide
Ascendia Pharmaceutical Solutions can support a seamless controlled substance program across formulation development, analytical activities, and cGMP manufacturing.
That capability is important to build confidence with sponsors as the controlled substance moves from formulation development into clinical manufacturing without transferring the program between multiple specialized providers.
Ascendia Pharmaceutical Solutions specializes in formulation, analytical, and manufacturing services and develops oral, topical, and injectable products. Its development capabilities include pre-formulation testing, formulation approach comparisons, dosage form design, formulation optimization, and transition into cGMP clinical manufacturing.
The controlled substance capability therefore operates within a broader drug development environment rather than as an isolated manufacturing service.
Controlled Substance Formulation Requires Careful Dose and Delivery Considerations
Formulation strategy becomes particularly important when developing a controlled substance as a drug product.
The finished dosage form must deliver the intended dose consistently while meeting requirements for stability, manufacturability, bioavailability, release, and patient use. Depending on the compound, the formulation may also need to address poor water solubility or other physicochemical challenges.
Ascendia Pharmaceutical Solutions' formulation expertise and proprietary technology platforms provide multiple approaches for addressing these challenges. Analytical rigor, stability, and scalable formulation are also important considerations when developing a controlled substance, particularly when the product must maintain consistent performance as it progresses from early development into manufacturing.
For controlled substances requiring specialized delivery, formulation and drug delivery technologies can help control how the active pharmaceutical ingredient is incorporated into the finished dosage form and how it is released. Liposome drug delivery represents one example of a specialized formulation approach that can be evaluated when a molecule presents challenges related to solubility, bioavailability, potency, stability, or drug release.
This type of formulation strategy can be particularly important when the therapeutic window is narrow and consistent dosing is critical to product performance and patient safety.
A Single CDMO Can Reduce Development Handoffs
Separating formulation development, analytical testing, and manufacturing among multiple vendors can introduce additional technology transfers and communication requirements.
Controlled substances add another consideration because material movement and inventory must remain appropriately controlled throughout the process.
Ascendia Pharmaceutical Solutions performs formulation development, analytical services, and manufacturing within its integrated development and manufacturing operation. Keeping these capabilities within one organization allows technical teams to work together as a formulation progresses toward manufacturing.
Ascendia Pharmaceutical Solutions' approach to technology transfer emphasizes early manufacturing involvement and continuity between formulation development and later-stage production. Its recent discussion of technology transfer in Phase II and Phase III addresses how early planning can reduce technical and operational risk as programs advance toward commercialization.
For a controlled substance program, that continuity can help reduce unnecessary risks associated with supply chain and material transfers while maintaining technical knowledge as the product moves through development.
A Controlled Substance Client Helped Drive the Need for Schedule II Capabilities
Ascendia Pharmaceutical Solutions' expansion into Schedule II controlled substances was driven in part by a specific client need.
The client may have the expertise and a technology platform for delivering a controlled substance but needs a development and manufacturing partner capable of combining that technology with formulation and manufacturing expertise to help support the development and commercialization of such products.
The product also needed to be manufactured in the United States to support its intended U.S. market and therapeutic applications.
Ascendia Pharmaceutical Solutions' existing formulation and manufacturing capabilities, combined with the ability to handle Schedule II controlled substances, created an opportunity for the two organizations to work together.
Ascendia Pharmaceutical Solutions was able to provide the formulation and manufacturing capabilities required to combine the client's delivery technology with the controlled substance formulation and advance the product toward U.S. development and manufacturing.
The example illustrates why DEA authorization can be an important part of a CDMO's broader capabilities. The license alone does not solve a formulation or manufacturing challenge. The value comes from combining controlled substance handling with the technical capabilities required to develop the finished drug product.
U.S.-Based Controlled Substance Manufacturing
U.S.-based manufacturing can be an important consideration for sponsors developing controlled substance products for the U.S. market.
Controlled substances can present additional considerations when materials or finished products move across international borders. Sponsors may therefore seek domestic development and manufacturing capabilities that can support the product without introducing unnecessary international transfers into the development pathway.
Ascendia Pharmaceutical Solutions provides U.S.-based formulation development and manufacturing from its facility in North Brunswick, New Jersey. Its DEA Schedule II registration adds controlled substance handling to an existing platform of formulation, analytical, and cGMP manufacturing capabilities.
For sponsors pursuing U.S. development or commercialization, the combination can provide a more direct development pathway while reducing the number of organizations involved in the program.
What Sponsors Should Look for in a Controlled Substance CDMO
A DEA registration should be one consideration when evaluating a CDMO for a controlled substance program. Sponsors should also evaluate whether the organization has the technical and operational infrastructure to support the entire development program.
Important considerations include the CDMO's DEA authorization, controlled substance storage and security, inventory reconciliation procedures, quality systems, analytical capabilities, formulation expertise, manufacturing capabilities, and experience transitioning development programs into cGMP production.
Sponsors should also consider how many technology transfers will be required during development and whether the CDMO can support multiple stages of the program under one organization.
An integrated model can reduce the number of handoffs between formulation, analytical, and manufacturing teams. It can also allow technical issues identified during formulation development to be addressed before they become manufacturing problems.
Ascendia Pharmaceutical Solutions' Fast, Flexible and First Time Right approach is built around this type of integration, with formulation development, analytical testing, and manufacturing capabilities operating within the same organization.
Controlled Substance Capabilities Should Support the Entire Development Strategy
A successful controlled substance program requires more than the ability to handle a regulated material.
The CDMO must understand how the controlled substance behaves within the formulation, how the formulation can be characterized analytically, how the process can be scaled, and how the finished product can be manufactured under cGMP conditions.
Ascendia Pharmaceutical Solutions brings these capabilities together with its DEA Schedule II registration.
The combination allows pharmaceutical and biotechnology companies to address controlled substance handling alongside formulation development, analytical testing, scale-up, and cGMP manufacturing.
That integrated approach can help sponsors maintain greater control over development timelines, technical continuity, and manufacturing strategy while working within the regulatory requirements associated with Schedule II substances.
Discuss a Controlled Substance Program With Ascendia Pharmaceutical Solutions
Sponsors developing products containing Schedule II controlled substances need a CDMO that can address regulatory controls without separating those requirements from the scientific work required to develop the drug product.
Ascendia Pharmaceutical Solutions combines DEA Schedule II capabilities with formulation development, analytical services, drug delivery technologies, and cGMP manufacturing in the United States.
For pharmaceutical and biotechnology companies evaluating a controlled substance development or manufacturing program, Ascendia Pharmaceutical Solutions can provide a single partner capable of supporting the program from formulation through manufacturing.
Contact Ascendia Pharmaceutical Solutions to discuss a controlled substance development program, evaluate formulation and manufacturing requirements, and schedule a meeting with the technical team.